Clinical trial · Observational
Diagnostic Study of Gene Alterations in Patients With Acute Myeloid Leukemia
Assessment of the Partial Tandem Duplication of ALL1 (MLL) in Patients With Acute Myeloid Leukemia- A CALGB Leukemia Tissue Bank Project
NCT00003931CI-TRIAL-00022826completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Diagnostic procedures, such as genetic testing, may improve the ability to detect acute myeloid leukemia and determine the extent of disease. PURPOSE: Diagnostic study to try to detect changes in the genes of patients who have acute myeloid leukemia.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Leukemia | Leukemia | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| reverse transcriptase-polymerase chain reaction | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- blood or bone marrow samples
- description
- All samples are obtained from specimens collected on CALGB-9665. No additional blood or bone marrow samples are collected CALGB-9769. Samples are examined by Southern blot analysis for gene rearrangement at 11q23. Samples showing evidence of ALL1 gene rearrangement are further analyzed by reverse transcription PCR amplification and/or cytogenetic analysis to detect partial tandem duplication of ALL1.
- interventionNames
- Genetic: reverse transcriptase-polymerase chain reaction
Primary outcomes (1)
- measure
- frequency of partial tandem duplication of ALL1 (MLL)
- timeFrame
- Up to 10 years
Secondary outcomes (1)
- measure
- predictive value of partial tandem duplication of ALL1
- timeFrame
- Up to 10 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 15 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Prior registration on protocol CALGB-9665 * Diagnosed with acute myeloid leukemia (AML) * Treated on a CALGB AML treatment protocol * Diagnostic bone marrow or blood specimen available PATIENT CHARACTERISTICS: Age: * 15 and over
References
Publications (0)
Data not yet available
No reference posted for this study.